EIF2AK3 and non-small cell lung carcinoma: Given that, blocking abnormal activation of pERK induced by the kinase cascade and co‐activating the specific phosphorylase activity to pERK may be a novel therapeutic strategy for further improving the survival rate of NSCLC patients.